PartnershipMay 19, 2026, 07:32 AM
Plus Therapeutics Partners with Ephemeral for AI Oncology Platform
AI Summary
Plus Therapeutics announced a strategic partnership with Ephemeral Technologies to create a unique AI execution platform for central nervous system (CNS) oncology. This platform will integrate and analyze Plus' proprietary therapeutic, diagnostic, and bioinformatics datasets to accelerate precision neuro-oncology. The collaboration aims to enhance operational efficiency in both laboratory and clinical settings, with further AI integration planned for future workflows and patient stratification.
Key Highlights
- Plus Therapeutics partnered with Ephemeral Technologies to develop an AI execution platform for CNS oncology.
- The platform will integrate and analyze Plus' therapeutic, diagnostic, and bioinformatics datasets.
- The goal is to accelerate precision neuro-oncology and improve patient survival for CNS cancers.
- Ephemeral Technologies was founded by former co-heads of Palantir Technologies' U.S. healthcare business.
- Plus anticipates tangible improvements in laboratory and clinical operating efficiency starting in 2026.
- The company plans to use AI for integrated operational workflows, decision support, and patient stratification beyond 2026.
- No financial terms of the agreement were disclosed.
Price Impact
More from PSTV